Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab
- Registration Number
- NCT06231121
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
The goal of this retrospective single-center chart review is to establish the response rate, efficacy and safety of a single dose of intravitreal faricimab injection in real-world patients with aflibercept- and ranibizumab-resistant neovascular age-related macular degeneration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients Faricimab Patients who received intravitreal faricimab injections between May and September, in 2023. and conform the inclusion/exclusion criteria.
- Primary Outcome Measures
Name Time Method Proportion of patients responding to the treatment switch 4 weeks Defined as reduction or disappearance of the intra- or subretinal fluid at 4 weeks following a single injection of faricimab
- Secondary Outcome Measures
Name Time Method Differences in patient characteristics between individuals responding and not responding to faricimab 4 weeks Changes in central retinal thickness after the treatment switch 4 weeks Measured on optical coherence tomography (OCT) scans
Changes in best-corrected visual acuity after the treatment switch 4 weeks Changes in pigment epithelium detachment (PED) height after the treatment switch 4 weeks Measured on optical coherence tomography (OCT) scans
Trial Locations
- Locations (1)
Miklos Schneider
🇩🇰Glostrup, Denmark